Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of Allocetra-OTS in adult sepsis with organ failure
NL-OMON53483Phase 2Withdrawn
- Sponsor
- Enlivex Therapeutics
- Start
- Sep 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in sepsis comparing Allocetra-OTS with Placebo (2 arms). Primary endpoints: Change from baseline in SOFA score throughout 28 days and Number and severity of adverse events and serious adverse events throughout 28 days. Planned start Sep 2022; status: withdrawn.
02
Drugs
Allocetra
03
Conditions
sepsis
Beyond the preview
Go deeper on NL-OMON53483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53483.